GCP
PMD

GSA Capital Partners’s Psychemedics Corporation PMD Stock Holding History

GSA Capital Partners’s Portfolio PMD Stock Details PMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,700
Closed -$215K – 2007
2017
Q1 		$215K Buy
10,700
+2,000
+23% +$43.9K 0.01% 1538
2016
Q4 		$215K Buy
+8,700
New +$195K 0.01% 1558

Other funds holding PMD

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIC
Crawford Investment Counsel Atlanta, Georgia $5.85B AUM 12.61% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

GSA Capital Partners's PMD Position: Q2 2017 in Review

GSA Capital Partners sold out of Psychemedics Corporation (PMD) in Q2 2017, closing a stake of 10,700 shares — an estimated $215K sold.

GSA Capital Partners first reported a position in PMD in Q4 2016 and held it in 2 quarters. The position peaked at $215K in Q1 2017. 58 funds tracked by Wall St. Rank hold PMD as of Q2 2017.

  • GSA Capital Partners reported no remaining Psychemedics Corporation position as of Q2 2017 after selling out during the quarter.
  • GSA Capital Partners sold 10,700 Psychemedics Corporation shares in Q2 2017, an estimated $215K.
  • GSA Capital Partners first reported a position in Psychemedics Corporation in Q4 2016 and held it in 2 quarters.
  • GSA Capital Partners's Psychemedics Corporation position peaked at $215K in Q1 2017.
  • 58 funds tracked by Wall St. Rank held Psychemedics Corporation as of Q2 2017.

Based on GSA Capital Partners's 13F filing for Q2 2017, filed 11 Aug 2017.